Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset VEEV
Coverage 166,249 Raw stories ingested 21,841 rewritten in CS_CZ • 7 to rewrite (last 2 days).
Agents 7 waiting Pipeline agents
  • FMP Stock News Fetch every minute 56s ago
  • FMP Forex News Fetch every 5 min 2m ago
  • CoinGecko News Fetch every 5 min 4m ago
  • FIO Stock News Fetch every 10 min 7m ago
  • Patria Stock News Fetch every 10 min 7m ago
  • Editorial rewrite Rewrite every minute 56s ago
  • Asset sync Assets every 1 hour 46m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-09-09 09:01 8h ago
2026-09-08 04:11 1d ago
Brown Lisle Cummings snížila podíl ve Veeva Systems
VEEV Veeva Systems
FMP Stock News 78
Original source text
Brown Lisle Cummings Inc. reduced its stake in Veeva Systems Inc. (NYSE:VEEV – Free Report) by 58.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,293 shares of the technology company’s stock after selling 10,120 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Veeva Systems were worth $1,294,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. California State Teachers Retirement System increased its holdings in shares of Veeva Systems by 16,590.3% during the second quarter. California State Teachers Retirement System now owns 39,388,224 shares of the technology company’s stock valued at $6,990,228,000 after acquiring an additional 39,152,230 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Veeva Systems by 7.0% in the 1st quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company’s stock worth $727,513,000 after purchasing an additional 271,252 shares in the last quarter. State Street Corp grew its position in Veeva Systems by 2.4% during the 4th quarter. State Street Corp now owns 3,589,425 shares of the technology company’s stock valued at $801,267,000 after purchasing an additional 85,695 shares during the last quarter. Geode Capital Management LLC increased its stake in Veeva Systems by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 3,172,716 shares of the technology company’s stock valued at $706,442,000 after purchasing an additional 23,117 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in Veeva Systems by 31.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,412,210 shares of the technology company’s stock valued at $706,078,000 after purchasing an additional 574,164 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analyst Upgrades and Downgrades VEEV has been the subject of several recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 target price on shares of Veeva Systems in a report on Thursday, August 27th. Canaccord Genuity Group boosted their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the stock a “hold” rating in a report on Thursday, August 27th. Royal Bank Of Canada upped their price objective on Veeva Systems from $275.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. The Goldman Sachs Group cut their target price on Veeva Systems from $190.00 to $165.00 and set a “sell” rating on the stock in a research note on Thursday, June 4th. Finally, Truist Financial lifted their target price on Veeva Systems from $262.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Veeva Systems presently has an average rating of “Moderate Buy” and a consensus price target of $284.46.

Read Our Latest Analysis on VEEV Veeva Systems Stock Down 0.4% Shares of VEEV stock opened at $274.02 on Tuesday. The company has a 50 day moving average price of $222.45 and a 200-day moving average price of $188.73. Veeva Systems Inc. has a 52 week low of $148.05 and a 52 week high of $310.50. The firm has a market capitalization of $44.37 billion, a PE ratio of 45.07, a P/E/G ratio of 1.17 and a beta of 0.97.

Veeva Systems (NYSE:VEEV – Get Free Report) last issued its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The company had revenue of $927.96 million for the quarter, compared to the consensus estimate of $905.38 million. During the same quarter in the prior year, the firm earned $1.99 earnings per share. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Analysts anticipate that Veeva Systems Inc. will post 6.7 earnings per share for the current year.

Insiders Place Their Bets In other news, insider Thomas Schwenger sold 10,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the transaction, the insider directly owned 19,449 shares of the company’s stock, valued at $5,471,587.17. This represents a 33.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.60% of the company’s stock.

Veeva Systems Company Profile (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Recommended Stories Five stocks we like better than Veeva Systems 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV – Free Report).

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
2026-09-03 20:14 5d ago
2026-09-03 14:41 6d ago
Veeva Systems překonala odhady a zvýšila výhled
VEEV Veeva Systems
FMP Stock News 78
Original source text
Key Takeaways Veeva Systems beat Q2 estimates, raised its fiscal 2027 outlook and advanced Vault CRM adoption.VEEV has more than 180 Vault CRM customers live, with commitments from 12 of the top 20 biopharmas.Veeva Systems' AI push is advancing, but market saturation and competition could constrain CRM growth. Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid second-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.

This Zacks Rank #3 (Hold) company’s shares have gained 25.7% in the year-to-date period compared with 11.3% growth of the industry. The S&P 500 Composite has increased 10.8% during the said time frame.

The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $45.6 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.7%.

Reasons Favoring VEEV’s GrowthDiversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.  

Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.

Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continued to advance in the second quarter of fiscal 2027, when Veeva Systems recorded its best CRM quarter and added two top-20 biopharma selections. Management said that Veeva Systems now has 12 of the top 20 CRM commitments, with two decisions remaining, up from 10 wins in the prior quarter.

More than 180 customers are live on Vault CRM, and one top-20 customer has enabled AI across its full field force. Commercial subscription revenues rose 13% year over year to $347.4 million, with management citing growth across CRM, content, data, Crossix and Ostro. The expanding live base supports ongoing migrations and creates opportunities to attach adjacent commercial applications as customers consolidate workflows on Vault.

Strong Q2 Results: Veeva Systems exited the second quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The company also raised its fiscal 2027 outlook. Strong execution across Commercial Solutions and R&D and Quality Solutions, along with continued momentum in newer growth areas, remained encouraging.

Veeva Systems continued to make notable progress with Vault CRM. The platform recorded its best quarter ever, with more than 180 customers live, including five top 20 biopharmas. In August, two additional top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, taking total top 20 commitments to 12 globally. A top 20 biopharma also deployed Vault CRM and Agentic Call Report across its entire U.S. field team during the quarter.

The company also advanced its AI strategy. Veeva Falcon, its agentic labor platform for clinical, regulatory and safety functions, now has five early adopters and remains on track for initial go-lives this year. Veeva Systems also acquired Copli and launched Veeva Falcon MLR to automate content reviews.

Vault AI added new standard agents, enhanced existing agents and introduced advanced tools for custom agent development in August. Management noted that customer interest in Falcon remains high, although product readiness and work with early adopters remain key near-term priorities.

Image Source: Zacks Investment Research

Factor That May Offset VEEV’s GainsMarket Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.

Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.          

Estimate TrendVeeva Systems is witnessing a positive estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has moved 17 cents north to $9.22.

The Zacks Consensus Estimate for third-quarter fiscal 2027 revenues is pegged at $933.8 million, indicating a 15.1% improvement from the year-ago quarter’s reported number. The consensus mark for fiscal third-quarter EPS is pegged at $2.33, implying a 14.2% improvement year over year.

Key PicksSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
2026-09-03 15:23 6d ago
2026-09-03 09:01 6d ago
Michael Burry bere zisky ve Veeva, ale má pro Snowflake ostré varování
VEEV Veeva Systems
FMP Stock News 72
Original source text
Michael Burry Takes Profits in Veeva. But He Has a Stark Warning for Snowflake Summary

Michael Burry trimmed his Veeva position after the shares rallied sharply while maintaining a bullish view on the software company

Michael Burry (Trades, Portfolio) has kept a bullish stance on Veeva Systems VEEV while reducing part of his holding after a rapid increase in the shares.

Burry disclosed the position earlier this year as part of a broader view that software stocks could recover. He later added to the investment before trimming it as Veeva approached a level he considered a potential barrier for further gains.

The move does not signal that Burry has abandoned the company. His comments indicate that valuation and the speed of the rally influenced the decision to reduce exposure rather than exit the investment.

Burry also raised concerns about Snowflake SNOW, describing its valuation as difficult to justify and pointing to potential long-term risks from cybersecurity developments involving artificial general intelligence and quantum computing.

Snowflake's shares, however, rose more than 23% in premarket trading after its latest results exceeded expectations. The company lifted its fiscal 2027 product-revenue forecast to $6.07 billion, representing 36% annual growth, from $5.84 billion previously.

Burry's Veeva trim may temper sentiment, while Snowflake's stronger outlook could offset valuation concerns.

Also check out:

Michael Burry Undervalued Stocks Michael Burry Top Growth Companies Michael Burry High Yield stocks, and Stocks that Michael Burry keeps buying Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure
2026-09-02 00:21 7d ago
2026-09-01 17:08 8d ago
Veeva spouští Falcon Safety pro bezpečnostní systémy podle normy E2B
VEEV Veeva Systems
FMP Stock News 72
Original source text
, /PRNewswire/ -- Veeva Systems (NYSE : VEEV) a annoncé aujourd'hui le lancement de Veeva Falcon Safety, une solution d'opérations de sécurité basée sur l'agentique, destinée à rationaliser la saisie des événements indésirables, le traitement des dossiers et leur suivi, afin de réduire les coûts, accélérer les processus et garantir la conformité des entreprises biopharmaceutiques de toutes tailles.

Outre son intégration transparente avec Veeva Safety, Falcon Safety assurera la gestion de la saisie et du suivi pour tout système de sécurité conforme à la norme E2B, y compris Oracle Argus et ArisGlobal LifeSphere MultiVigilance.

« Nous avons eu le privilège de travailler en étroite collaboration avec des gestionnaires de dossiers, des experts en pharmacovigilance et des spécialistes de la sécurité à l'échelle mondiale pour mettre au point Veeva Safety », a déclaré Marius Mortensen, vice-président chargé des produits Falcon chez Veeva. « Avec Falcon Safety, nous sommes ravis de renforcer ce partenariat et d'aider le secteur à réinventer ses procédures de sécurité. »

Devant être mis à la disposition des premiers utilisateurs en novembre 2026, Falcon Safety fait partie de Veeva AI, l'ensemble des solutions d'IA de Veeva destinées au secteur des sciences de la vie.

À propos de Veeva Systems
Veeva propose une plateforme cloud dédiée au secteur des sciences de la vie, comprenant des applications, des agents, des données et des services de conseil. Engagée en faveur de l'innovation, de l'excellence de ses produits et de la réussite de ses clients, Veeva compte plus de 1 500 clients, parmi lesquels figurent les plus grandes sociétés biopharmaceutiques mondiales et des biotechs émergentes. Véritable société d'utilité publique, Veeva s'engage à concilier au mieux les intérêts de toutes les parties prenantes, y compris les clients, les employés, les actionnaires et les industries qu'elle sert. Pour obtenir plus d'informations, consultez le site veeva.com.

Déclarations prospectives de Veeva
Le présent communiqué contient des déclarations prospectives concernant les produits et services de Veeva, ainsi que les résultats ou avantages attendus de l'utilisation de nos produits et services. Ces déclarations sont basées sur nos attentes actuelles. Les résultats réels pourraient différer sensiblement de ceux énoncés dans le présent communiqué, et nous ne sommes pas tenus de mettre à jour ces déclarations. Il existe de nombreux risques susceptibles d'avoir un impact négatif sur nos résultats, notamment les risques et incertitudes mentionnés dans notre rapport sur le formulaire 10-Q pour l'exercice clos le 31 juillet 2026, que vous pouvez consulter ici (un résumé des risques susceptibles d'avoir une incidence sur nos activités figure aux pages 33 et 34), ainsi que dans nos documents déposés ultérieurement auprès de la SEC, consultables à l'adresse sec.gov.
2026-08-31 11:02 9d ago
2026-08-26 16:05 14d ago
Veeva zvýšila výnosy o 18 procent, zisk vzrostl
VEEV Veeva Systems
FMP Stock News 92
Original source text
Total Revenues of $928.0M, up 18% Year Over Year
Subscription Revenues of $766.8M, up 16% Year Over Year

, /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.

"AI is opening up the next big chapter for Veeva and life sciences," said CEO Peter Gassner. "Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients."

Fiscal 2027 Second Quarter Results:

Revenues: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year. Operating Income and Non-GAAP Operating Income:(1) Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year. Net Income and Non-GAAP Net Income:(1) Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year. Net Income per Share and Non-GAAP Net Income per Share:(1) For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago. "Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board," said CFO Brian Van Wagener. "We continue to execute well across the business while also accelerating innovation and progress in new growth areas."

Recent Highlights:

Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry's fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter. Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development. Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training. Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:

Total revenues between $932 and $935 million. Non-GAAP operating income between $417 and $420 million.(2) Non-GAAP fully diluted net income per share between $2.33 and $2.34.(2) Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

Total revenues between $3,682 and $3,687 million. Non-GAAP operating income of about $1,640 million.(2) Non-GAAP fully diluted net income per share of approximately $9.21.(2) Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva's investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva's investor relations website.

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled "Non-GAAP Financial Measures" and the tables entitled "Reconciliation of GAAP to Non-GAAP Financial Measures" below for details.

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva's expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva's expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled "Summary of Risk Factors" on pages 33 and 34 in our filing on Form 10-Q for the period ended April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:

Media Contact:

Gunnar Hansen

Maria Scurry

Veeva Systems Inc.

Veeva Systems Inc.

267-460-5839

781-366-7617

[email protected]

[email protected]

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

July 31,
2026

January 31,
2026

Assets

Current assets:

Cash and cash equivalents

$    1,812,012

$    1,421,233

Short-term investments

5,430,935

5,139,581

Accounts receivable, net

496,677

1,259,737

Unbilled accounts receivable

68,970

50,609

Prepaid expenses and other current assets

137,633

126,470

Total current assets

7,946,227

7,997,630

Property and equipment, net

79,483

70,261

Deferred costs, net

27,835

29,961

Lease right-of-use assets

129,320

75,626

Goodwill

492,991

439,877

Intangible assets, net

55,647

30,314

Deferred income taxes

268,250

273,417

Other long-term assets

60,470

62,257

Total assets

$    9,060,223

$    8,979,343

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$       35,977

$       37,644

Accrued compensation and benefits

42,188

45,857

Accrued expenses and other current liabilities

49,634

45,885

Income tax payable

3,018

6,698

Deferred revenue

1,310,498

1,488,819

Lease liabilities

14,635

12,153

Total current liabilities

1,455,950

1,637,056

Deferred income taxes

2,056

558

Long-term lease liabilities

137,060

83,706

Other long-term liabilities

33,708

43,271

Total liabilities

1,628,774

1,764,591

Stockholders' equity:

Common stock

2

2

Additional paid-in capital

2,579,728

2,843,089

Accumulated other comprehensive (loss) income

(46,147)

8,160

Retained earnings

4,897,866

4,363,501

Total stockholders' equity

7,431,449

7,214,752

Total liabilities and stockholders' equity

$    9,060,223

$    8,979,343

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Revenues:

Subscription(3)

$      766,764

$      659,183

$    1,496,939

$    1,293,951

Professional services and other(4)

161,199

129,898

313,972

254,173

Total revenues

927,963

789,081

1,810,911

1,548,124

Cost of revenues(5):

Cost of subscription

105,677

93,830

204,780

172,176

Cost of professional services and other

126,335

101,423

248,156

196,901

Total cost of revenues

232,012

195,253

452,936

369,077

Gross profit

695,951

593,828

1,357,975

1,179,047

Operating expenses(5):

Research and development

222,918

192,677

431,241

376,710

Sales and marketing

126,701

109,439

237,818

208,067

General and administrative

71,314

95,804

140,786

164,630

Total operating expenses

420,933

397,920

809,845

749,407

Operating income

275,018

195,908

548,130

429,640

Other income, net

74,512

69,456

148,930

134,545

Income before income taxes

349,530

265,364

697,060

564,185

Income tax provision

76,101

65,055

162,695

135,686

Net income

$      273,429

$      200,309

$      534,365

$      428,499

Net income per share:

Basic

$          1.68

$          1.23

$          3.28

$          2.63

Diluted

$          1.66

$          1.19

$          3.22

$          2.56

Weighted-average shares used to compute net income per share:

Basic

162,344

163,496

162,836

163,129

Diluted

165,057

167,685

166,072

167,272

Other comprehensive income:

Net change in unrealized (loss) gain on available-for-sale investments

$      (26,490)

$      (11,300)

$      (53,941)

$        6,067

Net change in cumulative foreign currency translation gain (loss)

135

390

(366)

352

Comprehensive income

$      247,074

$      189,399

$      480,058

$      434,918

(3) Includes subscription revenues from the following product areas:

Veeva Commercial Solutions

$      347,389

$      307,523

$      685,255

$      612,934

Veeva R&D and Quality Solutions

419,375

351,660

811,684

681,017

Total subscription

$      766,764

$      659,183

$    1,496,939

$    1,293,951

(4) Includes professional services and other revenues from the following product areas:

Veeva Commercial Solutions

$       59,742

$       47,703

$      117,315

$       94,270

Veeva R&D and Quality Solutions

101,457

82,195

196,657

159,903

Total professional services and other

$      161,199

$      129,898

$      313,972

$      254,173

(5) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription

$        2,224

$        1,941

$        3,985

$        3,656

Cost of professional services and other

15,939

14,804

30,090

27,573

Research and development

62,220

53,388

113,783

101,337

Sales and marketing

27,886

25,392

52,480

47,713

General and administrative

28,534

26,441

55,724

53,897

Total stock-based compensation

$      136,803

$      121,966

$      256,062

$      234,176

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Six months ended July 31,

2026

2025

Cash flows from operating activities

Net income

$     534,365

$     428,499

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

22,458

19,948

Reduction of lease right-of-use assets

7,038

6,316

Accretion of discount on short-term investments

(2,841)

(4,535)

Stock-based compensation

256,062

234,176

Amortization of deferred costs

9,805

8,205

Deferred income taxes

26,529

31,699

Other, net

(1,127)

(1,414)

Changes in operating assets and liabilities:

Accounts receivable

768,314

593,032

Unbilled accounts receivable

(18,361)

(9,587)

Deferred costs

(7,679)

(7,721)

Prepaid expenses and other current and long-term assets

(21,394)

(21,232)

Accounts payable

(652)

3,361

Accrued expenses and other current liabilities

(1,578)

23,763

Income tax payable

(3,945)

(5,362)

Deferred revenue

(200,001)

(180,888)

Lease liabilities

(4,426)

(5,300)

Other long-term liabilities

3,258

2,631

Net cash provided by operating activities

1,365,825

1,115,591

Cash flows from investing activities

Purchases of short-term investments

(1,706,632)

(1,452,857)

Maturities and sales of short-term investments

1,345,987

1,023,691

Long-term assets

(9,773)

(12,213)

Acquisitions, net of cash acquired

(81,833)



Net cash used in investing activities

(452,251)

(441,379)

Cash flows from financing activities

Proceeds from exercise of common stock options

17,143

182,297

Repurchases of common stock

(472,673)



Taxes paid related to net share settlement of equity awards

(66,304)

(46,228)

Net cash (used in) provided by financing activities

(521,834)

136,069

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(831)

1,365

Net change in cash, cash equivalents, and restricted cash

390,909

811,646

Cash, cash equivalents, and restricted cash at beginning of period

1,423,412

1,120,963

Cash, cash equivalents, and restricted cash at end of period

$   1,814,321

$   1,932,609

Supplemental disclosures of other cash flow information:

Excess tax (deficiency) benefit from employee stock plans

$        (824)

$      15,610

Non-GAAP Financial Measures

In Veeva's public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefit (deficiency). Excess tax benefits (deficiencies) from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva finds it useful to exclude excess tax benefits (deficiencies) when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits (deficiencies), Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies. Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva's management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies. Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva's management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva's revenues earned during the periods presented and will contribute to Veeva's future period revenues as well. Litigation settlement-related charges. We exclude certain costs related to litigation settlements, including outcome-based payments to the law firms that represented us, because they are non-recurring and outside the ordinary course of business. Because these costs are unrelated to our day-to-day business operations, we believe excluding them enables more consistent evaluation of our operating results. Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures. There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva's management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands)

(Unaudited)

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Net cash provided by operating activities on a GAAP basis

$    238,709

$    238,433

$  1,365,825

$  1,115,591

Excess tax (benefit) deficiency from employee stock plans

(3,268)

(13,031)

824

(15,610)

Net cash provided by operating activities on a non-GAAP basis

$    235,441

$    225,402

$  1,366,649

$  1,099,981

Net cash used in investing activities on a GAAP basis

$    (63,540)

$   (389,272)

$   (452,251)

$   (441,379)

Net cash (used in) provided by financing activities on a GAAP basis

$   (259,308)

$    115,689

$   (521,834)

$    136,069

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Cost of subscription revenues on a GAAP basis

$    105,677

$     93,830

$    204,780

$    172,176

Stock-based compensation expense

(2,224)

(1,941)

(3,985)

(3,656)

Amortization of purchased intangibles

(1,072)

(1,046)

(1,746)

(2,058)

Cost of subscription revenues on a non-GAAP basis

$    102,381

$     90,843

$    199,049

$    166,462

Gross margin on subscription revenues on a GAAP basis

86.2 %

85.8 %

86.3 %

86.7 %

Stock-based compensation expense

0.3

0.3

0.3

0.3

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on subscription revenues on a non-GAAP basis

86.6 %

86.2 %

86.7 %

87.1 %

Cost of professional services and other revenues on a GAAP basis

$    126,335

$    101,423

$    248,156

$    196,901

Stock-based compensation expense

(15,939)

(14,804)

(30,090)

(27,573)

Amortization of purchased intangibles



(139)



(273)

Cost of professional services and other revenues on a non-GAAP basis

$    110,396

$     86,480

$    218,066

$    169,055

Gross margin on professional services and other revenues on a GAAP basis

21.6 %

21.9 %

21.0 %

22.5 %

Stock-based compensation expense

9.9

11.4

9.5

10.8

Amortization of purchased intangibles



0.1



0.2

Gross margin on professional services and other revenues on a non-GAAP basis

31.5 %

33.4 %

30.5 %

33.5 %

Gross profit on a GAAP basis

$    695,951

$    593,828

$  1,357,975

$  1,179,047

Stock-based compensation expense

18,163

16,745

34,075

31,229

Amortization of purchased intangibles

1,072

1,185

1,746

2,331

Gross profit on a non-GAAP basis

$    715,186

$    611,758

$  1,393,796

$  1,212,607

Gross margin on total revenues on a GAAP basis

75.0 %

75.3 %

75.0 %

76.2 %

Stock-based compensation expense

2.0

2.1

1.9

2.0

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on total revenues on a non-GAAP basis

77.1 %

77.5 %

77.0 %

78.3 %

Research and development expense on a GAAP basis

$    222,918

$    192,677

$    431,241

$    376,710

Stock-based compensation expense

(62,220)

(53,388)

(113,783)

(101,337)

Amortization of purchased intangibles

(270)



(270)



Research and development expense on a non-GAAP basis

$    160,428

$    139,289

$    317,188

$    275,373

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Sales and marketing expense on a GAAP basis

$    126,701

$    109,439

$    237,818

$    208,067

Stock-based compensation expense

(27,886)

(25,392)

(52,480)

(47,713)

Amortization of purchased intangibles

(2,720)

(2,890)

(5,051)

(5,685)

Sales and marketing expense on a non-GAAP basis

$     96,095

$     81,157

$    180,287

$    154,669

General and administrative expense on a GAAP basis

$     71,314

$     95,804

$    140,786

$    164,630

Stock-based compensation expense

(28,534)

(26,441)

(55,724)

(53,897)

Litigation settlement-related charges



(30,627)



(30,627)

General and administrative expense on a non-GAAP basis

$     42,780

$     38,736

$     85,062

$     80,106

Operating expense on a GAAP basis

$    420,933

$    397,920

$    809,845

$    749,407

Stock-based compensation expense

(118,640)

(105,221)

(221,987)

(202,947)

Amortization of purchased intangibles

(2,990)

(2,890)

(5,321)

(5,685)

Litigation settlement-related charges



(30,627)



(30,627)

Operating expense on a non-GAAP basis

$    299,303

$    259,182

$    582,537

$    510,148

Operating income on a GAAP basis

$    275,018

$    195,908

$    548,130

$    429,640

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges



30,627



30,627

Operating income on a non-GAAP basis

$    415,883

$    352,576

$    811,259

$    702,459

Operating margin on a GAAP basis

29.6 %

24.8 %

30.3 %

27.8 %

Stock-based compensation expense

14.7

15.5

14.1

15.1

Amortization of purchased intangibles

0.5

0.5

0.4

0.5

Litigation settlement-related charges



3.9



2.0

Operating margin on a non-GAAP basis

44.8 %

44.7 %

44.8 %

45.4 %

Net income on a GAAP basis

$    273,429

$    200,309

$    534,365

$    428,499

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges



30,627



30,627

Income tax effect on non-GAAP adjustments(6)

(26,882)

(23,572)

(38,945)

(40,085)

Net income on a non-GAAP basis

$    387,412

$    333,406

$    758,549

$    661,234

Diluted net income per share on a GAAP basis

$        1.66

$        1.19

$        3.22

$        2.56

Stock-based compensation expense

0.83

0.73

1.54

1.40

Amortization of purchased intangibles

0.02

0.02

0.04

0.05

Litigation settlement-related charges



0.18



0.18

Income tax effect on non-GAAP adjustments(6)

(0.16)

(0.13)

(0.23)

(0.24)

Diluted net income per share on a non-GAAP basis

$        2.35

$        1.99

$        4.57

$        3.95

________________________
(6) For the three and six months ended July 31, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%.

SOURCE Veeva Systems
2026-08-31 11:01 9d ago
2026-08-26 22:59 13d ago
Veeva Systems oznámila hospodářské výsledky za 2. fiskální čtvrtletí
VEEV Veeva Systems
FMP Stock News 78
Original source text
Veeva Systems Inc. (VEEV) Q2 2027 Earnings Call August 26, 2026 5:00 PM EDT

Company Participants

Gunnar Hansen - Director of Investor Relations
Peter Gassner - Founder, CEO & Director
Brian Van Wagener - Chief Financial Officer
Paul Shawah - Executive Vice President of Strategy & Campaign Manager

Conference Call Participants

Joseph Vruwink - Robert W. Baird & Co. Incorporated, Research Division
Brian Peterson - Raymond James & Associates, Inc., Research Division
Hoi-Fung Wong - Oppenheimer & Co. Inc., Research Division
Ryan Powderly-Gross - Barclays Bank PLC, Research Division
Alexei Gogolev - JPMorgan Chase & Co, Research Division
David Windley - Jefferies LLC, Research Division
Rishi Jaluria - RBC Capital Markets, Research Division
Tyler Radke - Citigroup Inc., Research Division
Jailendra Singh - Truist Securities, Inc., Research Division
Craig Hettenbach - Morgan Stanley, Research Division
Andrew DeGasperi - BNP Paribas, Research Division
Dylan Becker - William Blair & Company L.L.C., Research Division
Tamjid Md Moinuddin Chowdhury - Guggenheim Securities, LLC, Research Division
William Fitzsimmons - Piper Sandler & Co., Research Division
Ryan MacDonald - Needham & Company, LLC, Research Division
Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division

Presentation

Operator

Hello, everyone. Thank you for joining us, and welcome to the Veeva Systems Fiscal 2027 Second Quarter Results Conference Call. [Operator Instructions] I will now hand the conference over to Gunnar Hansen, Senior Director, Investor Relations. Gunnar, please go ahead.

Gunnar Hansen
Director of Investor Relations

Good afternoon, and welcome to Veeva's Fiscal 2027 Second Quarter Earnings Conference Call for the quarter ended July 31, 2026. As a reminder, we posted prepared remarks on Veeva's Investor Relations website just after 1:00 p.m. Pacific today. We hope you've had a chance to read them before the call. Today's call will be used primarily for Q&A. With me today for Q&A are Peter Gassner, our Chief Executive Officer; Paul Shawah, EVP, Strategy; and Brian Van Wagener, our Chief Financial Officer.
2026-08-31 11:01 9d ago
2026-08-27 04:43 13d ago
American Capital nakoupila podíl ve Veeva Systems
VEEV Veeva Systems
FMP Stock News 78
Original source text
American Capital Management Inc. purchased a new stake in shares of Veeva Systems Inc. (NYSE:VEEV – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 196,848 shares of the technology company’s stock, valued at approximately $34,935,000. Veeva Systems makes up about 1.6% of American Capital Management Inc.’s investment portfolio, making the stock its 26th biggest position. American Capital Management Inc. owned about 0.12% of Veeva Systems as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Sivia Capital Partners LLC increased its stake in Veeva Systems by 225.9% in the second quarter. Sivia Capital Partners LLC now owns 3,122 shares of the technology company’s stock worth $899,000 after purchasing an additional 2,164 shares during the period. Bank of Nova Scotia grew its holdings in shares of Veeva Systems by 44.5% in the second quarter. Bank of Nova Scotia now owns 5,866 shares of the technology company’s stock worth $1,689,000 after purchasing an additional 1,806 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Veeva Systems by 34.6% in the second quarter. NewEdge Advisors LLC now owns 8,832 shares of the technology company’s stock worth $2,543,000 after purchasing an additional 2,272 shares during the last quarter. Treasurer of the State of North Carolina increased its stake in Veeva Systems by 2.2% in the 2nd quarter. Treasurer of the State of North Carolina now owns 68,950 shares of the technology company’s stock worth $19,856,000 after buying an additional 1,452 shares during the period. Finally, Diversify Wealth Management LLC increased its stake in Veeva Systems by 5.3% in the 2nd quarter. Diversify Wealth Management LLC now owns 11,399 shares of the technology company’s stock worth $3,140,000 after buying an additional 575 shares during the period. Institutional investors own 88.20% of the company’s stock.

Trending Headlines about Veeva Systems Here are the key news stories impacting Veeva Systems this week:

Positive Sentiment: Veeva reported second-quarter revenue of approximately $928 million, up 17.6% year over year and above the $905.4 million consensus estimate. Subscription revenue rose 16% to $766.8 million. Veeva Announces Fiscal 2027 Second Quarter Results Positive Sentiment: Adjusted earnings reached $2.35 per share, exceeding the $2.22 consensus estimate and increasing from $1.99 a year earlier. The earnings and revenue beats were approximately 5.9% and 2.6%, respectively. Veeva Systems Q2 Earnings and Revenues Beat Estimates Positive Sentiment: Management issued above-consensus fiscal 2027 guidance, including revenue of about $3.7 billion versus a $3.6 billion estimate and EPS of $9.21 versus an $8.58 estimate. Third-quarter revenue guidance of $932 million-$935 million and EPS guidance of $2.33-$2.34 also topped analyst forecasts. Positive Sentiment: Biogen and Regeneron each committed to adopting Veeva Vault CRM globally. The wins reinforce Veeva’s competitive position in life-sciences customer relationship management and may support future subscription growth. Veeva Vault CRM Selected by Regeneron Veeva Vault CRM Selected by Biogen Neutral Sentiment: Piper Sandler initiated coverage, while Needham reaffirmed its Buy rating. These actions add analyst visibility but provide limited new information without detailed price targets or estimates. Neutral Sentiment: Despite the improving outlook, Veeva trades at a relatively elevated valuation, with a reported price-to-earnings ratio above 43. Future gains may therefore depend on continued execution and strong growth. Insider Activity In other Veeva Systems news, insider Thomas D. Schwenger sold 36,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $250.23, for a total value of $9,008,280.00. Following the completion of the transaction, the insider directly owned 19,449 shares of the company’s stock, valued at approximately $4,866,723.27. The trade was a 64.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.60% of the stock is currently owned by company insiders. Analyst Ratings Changes A number of brokerages recently issued reports on VEEV. Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Wells Fargo & Company lifted their target price on Veeva Systems from $317.00 to $320.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. The Goldman Sachs Group lowered their target price on Veeva Systems from $190.00 to $165.00 and set a “sell” rating for the company in a report on Thursday, June 4th. Needham & Company LLC reissued a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a research report on Monday. Finally, Citigroup raised their price target on Veeva Systems from $176.00 to $190.00 and gave the company a “neutral” rating in a research note on Thursday, June 4th. Nineteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $258.08.

Check Out Our Latest Stock Analysis on VEEV

Veeva Systems Stock Down 0.8% VEEV opened at $244.72 on Thursday. The company has a market cap of $39.75 billion, a P/E ratio of 43.62, a price-to-earnings-growth ratio of 1.06 and a beta of 0.92. The firm’s 50-day moving average price is $203.41 and its 200-day moving average price is $183.04. Veeva Systems Inc. has a 52-week low of $148.05 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV – Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. The firm had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, research analysts anticipate that Veeva Systems Inc. will post 6.65 EPS for the current fiscal year.

Veeva Systems Profile (Free Report)

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.

Read More Five stocks we like better than Veeva Systems Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise Alcoa’s Gallium Project Opens a New Door Beyond Aluminum Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech Can Tesla’s Flying Roadster Distract From Its Real Risks?

Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.
2026-07-15 15:54 1mo ago
2026-07-15 10:05 1mo ago
Veeva Systems překonala odhady díky růstu služeb předplatného
VEEV Veeva Systems
FMP Stock News 72
Original source text
Key Takeaways VEEV topped Q1 fiscal 2027 earnings and revenue estimates, led by Subscription services growth.VEEV's Vault CRM has 150 live customers, 40 migrations and over 80% overall win rate.VEEV is expanding AI offerings, with Ostro serving over 50 brands and Vault AI due in August. Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern.

This Zacks Rank #3 (Hold) company’s shares have lost 13.5% in the year-to-date period compared with the 5.9% decline of the industry. The S&P 500 composite has increased 9.7% during the said time frame.

The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $31.97 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.5%.

Image Source: Zacks Investment Research

Reasons Favoring VEEV’s GrowthDiversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem.  

Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions.

Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continues to build as large customers move off legacy CRM deployments and standardize commercial workflows. Management highlighted recent global selections from Teva and Merck KGaA and noted that Veeva Systems has secured 10 wins compared with six for Salesforce, within its defined top 20 cohort, with four decisions still pending.

The company also cited an overall Vault CRM win rate above 80% and more than 150 customers live, supported by over 40 completed migrations. This installed base creates a multi-year services and subscription runway and should support the attachment of adjacent commercial applications.

Strong Q1 Results: Veeva Systems exited the first quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.

Veeva Systems continues to strengthen its position in life sciences software through rapid innovation in artificial intelligence and expanding customer adoption. During the fiscal first quarter, the company significantly advanced its industry-specific AI strategy. Ostro, acquired in March, is now delivering compliant conversational AI for more than 50 brands, while Vault AI remains on track for deployment across all Vault applications in August.

Factor That May Offset VEEV’s GainsMarket Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition.

Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates.          

Estimate TrendVeeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $9.05.

The Zacks Consensus Estimate for second-quarter fiscal 2027 revenues is pegged at $904.1 million, indicating a 14.6% improvement from the year-ago quarter’s reported number. The EPS estimate for the second quarter of fiscal 2027 is pinned at $2.22, implying a 11.6% improvement year over year.

Key PicksSome better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
2026-07-03 18:36 2mo ago
2026-07-03 12:31 2mo ago
Veeva zvýšila výhled po silném čtvrtletí
VEEV Veeva Systems
FMP Stock News 78
Original source text
It has been about a month since the last earnings report for Veeva Systems (VEEV - Free Report) . Shares have added about 7.9% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Veeva due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

Veeva Systems Q1 Earnings & Revenues Beat, Operating Margin RiseVeeva Systems reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted earnings per share beat the Zacks Consensus Estimate by 5.2%.

GAAP earnings per share in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37.

VEEV’s Q1 Revenue DetailsIn the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%.

The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance.

Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services and Professional services and other.

In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions.

Professional services and other revenues increased 22.9% year over year to $152.8 million.

Q1 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%.

Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year.

Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%.

VEEV’s Financial PositionThe company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end.

Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago.

Q2 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027.

For the fiscal second quarter, the company expects total revenues between $902 million and $905 million. The Zacks Consensus Estimate is currently pegged at $886.8 million.

Subscription revenues are estimated to be approximately $754 million, and revenues for Professional services and other are expected to be in the range of $148-$151 million for the fiscal second quarter.

For the fiscal second quarter, adjusted earnings per share is anticipated to be between $2.21 and $2.22. The Zacks Consensus Estimate is pegged at $2.19.

Veeva Systems now expects revenues for fiscal 2027 between $3,635 million and $3,645 million. The Zacks Consensus Estimate is currently pegged at $3.59 billion.

For fiscal 2027, Subscription revenues are now expected to be approximately $3,060 million. This consists of Commercial Solutions’ subscription revenues of around $1,395 million and R&D Solutions’ subscription revenues of approximately $1,665 million.

Professional services and other revenues for fiscal 2027 are now expected to be between $575 million and $580 million.

Adjusted earnings per share for fiscal 2027 is now expected to be approximately $9.05. The Zacks Consensus Estimate is pegged at $8.86.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

VGM ScoresAt this time, Veeva has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Veeva has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
2026-06-29 18:44 2mo ago
2026-06-29 13:31 2mo ago
Veeva koupila Copli a spustila Falcon MLR
VEEV Veeva Systems
FMP Stock News 86
Original source text
Key Takeaways VEEV acquired Copli and launched Falcon MLR to automate life sciences content reviews.Falcon MLR integrates with PromoMats to check content against labels and country rules.VEEV says Falcon MLR could eliminate over 70% of manual MLR labor in five years. Veeva Systems (VEEV - Free Report) has strengthened its artificial intelligence (AI)-driven commercial content capabilities with the acquisition of Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Alongside the acquisition, the company launched Veeva Falcon MLR, an AI-powered solution designed to accelerate content review and approval processes.

From an investor's standpoint, the acquisition expands Veeva's AI portfolio and enhances the value proposition of its commercial cloud offerings. By embedding agentic automation into the MLR workflow, the company is likely to drive stronger customer adoption, deepen platform stickiness and create additional cross-selling opportunities, which could support long-term revenue growth and strengthen its competitive position in the life sciences software market.

Likely Trend of VEEV Stock Following the NewsShares of VEEV have traded flat since the announcement on June 23. In the year-to-date period, shares of the company lost 23.3% compared with the industry’s 10.9% decline.  The S&P 500 increased 7.1% in the same time frame.

The launch of Veeva Falcon MLR is expected to strengthen Veeva's long-term growth prospects by expanding its AI-driven product portfolio and increasing the strategic value of its Commercial Cloud platform. As pharmaceutical and biotechnology companies seek to accelerate content approvals while maintaining regulatory compliance, Falcon MLR can help streamline one of the industry's most time-consuming workflows through agentic automation.

Its seamless integration with Veeva PromoMats is likely to drive broader customer adoption, improve client retention and create cross-selling opportunities across Veeva's installed base, reinforcing recurring subscription revenues and the company's leadership in life sciences software.

VEEV currently has a market capitalization of $27.84 billion.

Image Source: Zacks Investment Research

More on the NewsVeeva Falcon MLR is an agentic MLR solution that automates the review of promotional and medical content for life sciences companies. Built on Copli's technology and integrated with Veeva PromoMats, the solution conducts compliance checks against approved product labels and country-specific regulations, enabling marketing teams, MLR reviewers and agencies to streamline the review and approval process. According to Veeva, Falcon MLR has the potential to eliminate more than 70% of manual MLR labor over the next five years, significantly shortening review cycles while improving operational efficiency.

The launch is expected to primarily strengthen Veeva's Commercial Cloud business, particularly its Content Management portfolio led by PromoMats. PromoMats is widely used by pharmaceutical and biotechnology companies to manage the creation, review, approval and distribution of compliant promotional content. By embedding agentic AI directly into this workflow, Veeva enhances the functionality of an already mission-critical application, increasing customer value while making its commercial content ecosystem more intelligent and difficult to replace. The addition of Falcon MLR also complements Veeva's broader Falcon AI portfolio, reinforcing the company's strategy of integrating AI capabilities across its cloud applications.

The acquisition of Copli further expands Veeva's AI expertise and accelerates the commercialization of agentic automation across the life sciences industry. As demand for AI-powered compliance and content management solutions continues to rise, Falcon MLR positions Veeva to capture incremental growth opportunities while strengthening its competitive moat in life sciences software.

Favorable Industry Prospect for VEEVPer a report by Grand View Research, the global agentic AI in healthcare market size was estimated at $538.51 million in 2024 and is projected to reach $4.96 billion by 2030, expanding at a CAGR of 45.56%.

The rising automation of repetitive tasks, growing focus on cost and resource optimization, and increasing adoption of enhanced patient care solutions are factors contributing to market growth. 

A Recent Development by VEEVRecently, VEEV announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness.

Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.

WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
2026-06-26 16:34 2mo ago
2026-06-26 12:00 2mo ago
Veeva spustila EHS v Quality Cloud
VEEV Veeva Systems
FMP Stock News 78
Original source text
Key Takeaways Veeva launched EHS within Quality Cloud to help sites manage operational and environmental risks.VEEV shares fell 2% after the news, with the stock down 29.2% year to date.Veeva EHS automates incident reporting, investigations and compliance workflows on one platform. Veeva Systems (VEEV - Free Report) recently announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness.

Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution. The company believes organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention.

Veeva EHS is expected to be available to early adopters in August 2026.

Likely Trend of VEEV Stock Following the NewsFollowing the announcement, VEEV shares lost 2% at yesterday’s closing. Year to date, the stock has declined 29.2%, underperforming the industry’s 15.2% fall and the S&P 500’s 7.3% rise.

The launch of Veeva EHS is expected to strengthen Veeva’s position in the EHS software market by expanding its Quality Cloud portfolio. The unified platform can drive higher customer adoption, improve cross-selling opportunities and increase recurring revenues. Its automation, real-time risk visibility and integrated compliance capabilities also enhance Veeva's competitive advantage over legacy EHS solution providers, supporting long-term business growth.

VEEV currently has a market capitalization of $26.21 billion.

Image Source: Zacks Investment Research

More on Veeva EHSVeeva EHS enables organizations to report safety incidents in real time, manage investigations from start to finish and automate compliance workflows within a single platform. The solution integrates with Veeva QMS and Veeva Training, allowing safety events to automatically create quality deviations and assign relevant training. This eliminates duplicate data entry, streamlines workflows and helps organizations maintain compliance.

According to Bobbie Grant, Global Senior EHS Manager at Thermo Fisher Scientific, a modern EHS platform with unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency. Grant added that Veeva provides an advanced solution that can maintain data integrity and provide the foundation for AI-driven capabilities to reduce risk over time.

Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the environmental health and safety (EHS) software market is valued at $8.9 billion in 2026 and is expected to witness a CAGR of 8.1% through 2030.

Factors like the stringent regulatory requirements that healthcare and life science organizations must navigate, digital transformation initiatives in healthcare and life sciences, a growing focus on workplace safety and risk reduction, and the integration of AI and machine learning are boosting the market’s growth.

Other NewsVeeva recently acquired Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Copli is available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years.

VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .

BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.

BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.

Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.